Can Targeting Proliferative Signaling Pathways Be an Effective Cancer Therapy?
Yes, targeting these pathways is a key strategy in cancer therapy. Drugs that inhibit specific components of proliferative signaling, such as tyrosine kinase inhibitors and monoclonal antibodies against growth factor receptors, have shown efficacy in treating certain cancers. However, resistance often develops, necessitating combination therapies or novel agents to overcome this challenge.
